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Abstract
Recall by genotype (RbG) studies aim to better understand the phenotypes that correspond to genetic variants of interest, by
recruiting carriers of such variants for further phenotyping. RbG approaches pose major ethical and legal challenges related to
the disclosure of possibly unwanted genetic information. The Cooperative Health Research in South Tyrol (CHRIS) study is a
longitudinal cohort study based in South Tyrol, Italy. Demand has grown for CHRIS study participants to be enrolled in RbG
studies, thus making the design of a suitable ethical framework a pressing need. We here report upon the design of a pilot RbG
study conducted with CHRIS study participants. By reviewing the literature and by consulting relevant stakeholders (CHRIS
participants, clinical geneticists, ethics board, GPs), we identified key ethical issues in RbG approaches (e.g. complexity of the
context, communication of genetic results, measures to further protect participants). The design of the pilot was based on a
feasibility assessment, the selection of a suitable test case within the ProtectMove Research Unit on reduced penetrance of
hereditary movement disorders, and the development of appropriate recruitment and communication strategies. An empirical
study was embedded in the pilot study with the aim of understanding participants’ views on RbG. Our experience with the
pilot study in CHRIS allowed us to contribute to the development of best practices and policies for RbG studies by drawing
recommendations: addressing the possibility of RbG in the original consent, implementing tailored communication strategies,
engaging stakeholders, designing embedded empirical studies, and sharing research experiences and methodology.
Introduction
The unprecedented amount of human genomic data gener-
ated by next-generation sequencing (NGS) in different
research settings, including population biobank projects, is
an important resource to advance our understanding of both
health and disease. However, the richness of the genetic
data now attainable through NGS calls for similar levels of
detail in terms of the accompanying phenotype(s). In this
context, re-inviting or recruiting research participants for
deeper phenotyping, based upon the presence or absence of
certain genetic variants in an approach termed “recall by
genotype” (RbG) or “genotype-driven research recruit-
ment”, is gaining increasing importance. The rationale for
RbG is that drawing upon the potential biological impact of
the variants in question already at recruitment can render the
subsequent phenotyping process more specific and cost-
effective [1].
The process of re-inviting individuals who already par-
ticipated in a research project may seem unproblematic at
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first glance, but it nevertheless poses a challenge to estab-
lished ethical, legal, and practical research frameworks, and
therefore warrants further consideration [2, 3]. In fact,
patient-based medical research generally proceeds under the
proviso that a potential study participant receives all the
information necessary to make an autonomous decision
about their participation, or not, during the enrolment phase
of the study. This also holds legal constrains in Italy where
genetic data can only be communicated based on the indi-
vidual informed choice and often genetic counselling is
required [4]. When participants are approached because of
their genotype, however, communicating the reason for the
contact may already entail the disclosure of sensitive
information that the individual may not actually wish to
know [3, 5–7].
Designing an RbG process requires several decisions to be
made upfront [2]. First, the genetic details to be commu-
nicated to the study participants must be determined. Whether
a particular genotype is problematic to report depends upon
whether such genotype is known to have a deleterious phe-
notypic effect or not or whether it comprises a new, hitherto
unknown, variant. Second, the means must be provided to
ascertain the participants’ preferences about the feedback of
potentially problematic information. Both these issues relate
to the ongoing debate about the extent to which researchers
are obliged to return individual research results to study
participants. In genetic research, study subjects are usually
informed beforehand about the type of variants to be analysed
and, in the course of consenting, can be given some form of
counselling allowing them to weigh up the pros and cons of
receiving individual research results [8–11]. In the context of
RbG, careful consideration must therefore be given to the
informed consent process, particularly to the kind of infor-
mation provided about future research and whether it poten-
tially involves RbG [6, 12, 13].
The number of studies relying upon RbG can be
expected to increase considerably in the near future, and
several ad hoc cohorts (e.g. the Oxford biobank [14]) have
been set up specifically for pursuing this type of research
[1]. Members of such cohorts should be aware of the pos-
sibility that they may be re-contacted for further research,
based upon their genetic make-up. On the other hand, in
population studies where RbG was not foreseen at the
outset, re-call could be performed without revealing the
main reason for it. While such an approach may appear
unacceptable on principle, currently, there are no recog-
nized ethical and legal standards for RbG in cohorts where
RbG was not planned and which was therefore not included
in the original informed consent [2, 6, 15, 16].
The Cooperative Health Research in South Tyrol
(CHRIS) study is a longitudinal cohort study targeting the
general population of Val Venosta in South Tyrol, Italy.
CHRIS was launched in 2011 to investigate the molecular
basis of common chronic diseases associated with human
ageing and to analyse the interaction of genetic factors with
life-style and environmental factors [17]. Baseline assess-
ment in CHRIS comprised screening of the cardiovascular,
metabolic, neurological, and psychosocial health status of
13,389 participants, representing 45% of the adult inhabi-
tants of the valley. The biobank of the CHRIS study
includes a vast collection of biosamples (blood, urine, cells,
DNA). Genetic data obtained from the DNA can potentially
be used in several studies, including also RbG studies,
which were not planned at the time of recruitment. CHRIS
promotes a participant-centric approach by considering the
interests, needs, and demands of participants at all the steps
of the research study [17, 18]. With the growing demand for
RbG studies, we realized that CHRIS needed to develop an
ethically acceptable and legally sound RbG framework. The
aim of the present paper is to describe the steps taken to
develop such a framework, by designing and implementing
a pilot RbG study and by showing how we addressed the
ethical issues and the legal requirements associated with
RbG in the process. Moreover, our experience with an RbG
pilot study in CHRIS allowed us to draw some general
recommendations for policy development in such studies.
Workflow
When designing the pilot RbG study, we decided to also
embed within it an empirical study, including qualitative
and quantitative parts. The empirical study was designed to
collect direct feedback from participants who were involved
in an RbG study. This was important not only for under-
standing participants’ experience while participating in our
pilot RbG study (feedback on the recruitment and com-
munication strategy) but also for understanding their views
on RbG-designed studies in general (interest in participat-
ing, preference regarding re-contact, and concerns). The
pilot RbG study and the embedded empirical study were
conducted in August 2018 at the CHRIS centre in Silandro/
Schlanders, Italy. The studies are a joint effort by Eurac
Research, Institute for Biomedicine, Bolzano, Italy, and the
University of Lübeck, Germany, made as part of a wider
scientific project on reduced penetrance in movement dis-
orders (ProtectMove). The pilot study comprised a clinical
examination (neurological function assessment), whereas
the empirical study consisted of two questionnaires (one
administered before the clinical examination and the other
after the clinical examination and before leaving the study
location) and an interview (conducted after the clinical
examination). The whole study (comprising the pilot and
the embedded empirical study) was performed in accor-
dance with the Declaration of Helsinki and was approved by
the ethics committee of the Azienda Sanitaria dell’Alto
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Adige. All participants provided written consent to partici-
pate in the study. Here, we describe the design of the pilot
study and the policy building process, drawing on some
preliminary observations made in the empirical study which
shed light on the RbG process. The methodological details
and the results of the empirical study will be published
elsewhere.
The stepwise strategy we took in order to conduct a pilot
RbG study in the frame of the CHRIS study is shown in
Fig. 1. Through a narrative literature review, we identified
the key issues associated with RbG studies, and the practical
recommendations that were drawn from on how to conduct
an RbG study in an ethically acceptable way. In the design
of both the pilot study and the embedded empirical study,
we took into account the views and suggestions of different
stakeholders (clinical geneticists, general practitioners
(GPs), ethics committee, CHRIS participants). In details, we
discussed with clinical geneticists in order to identify leg-
ally sound and ethically sustainable strategies for the
communication of genetic information; we consulted the
ethics committee and GPs to ensure we included measures
to safeguard participants in the pilot study; the experience of
an earlier empirical study on return of results conducted
with CHRIS participants (own unpublished observations)
allowed us to design the questionnaire for the embedded
quantitative study. The design of the pilot included a fea-
sibility assessment, the identification of the test case, the
choice of the recruitment strategy, and a communication
strategy.
Identification of relevant RbG ethical issues
In the narrative literature review, papers focused on the
ethical aspects related to RbG (from here referred as “ethical
RbG papers”) and papers focused on the biomedical and
clinical aspects of RbG-designed studies, aiming at under-
standing the phenotypic effect of specific genetic variants
(from here referred as “biomedical RbG papers”) were
reviewed. We sought to understand how to balance scien-
tific interests and participants’ rights. We expected to find,
in the biomedical RbG papers, the translation into practice
Fig. 1 Design of the pilot RbG
study and RbG policy building
process in CHRIS. The figure
summarizes the workflow of the
present study, showing a multi-
step process as a model for RbG
study design and policy
development.
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of the ethical issues discussed in the ethical papers, and
approaches to the challenges that an RbG-designed
study poses.
The ethical papers were mostly focused on the perspec-
tive of participants to RbG: authors investigated partici-
pants’ understanding of the rationale of RbG-designed
studies [15], the experience of participation in genetic
research [15, 19, 20], the expectations associated with and
the experience of recruitment in RbG studies [19, 21], and
the communication of individual genetic results (meanings
of genetic results, disclosure) [15, 20–23] (Table 1).
Importantly, they highlighted that the “context” may
influence the steps to be taken while designing RbG studies,
especially in the process of re-contact and the commu-
nication (or not) of genetic research results. The discussed
contextual factors included:
(1) The participant’s relationship with the researchers
involved [22, 24].
(2) The modality of re-contact, i.e. in which way and by
whom the re-contact is made [24].
(3) The nature of the target participants population (general
population or disease-specific cohort) [21–23].
(4) The possible involvement of other family members [24].
(5) The focus of the RbG study compared to that of the
original study [24].
(6) For participants from a disease-specific cohort or for
parents of minors with a disease: disease status, type and
nature of the condition being studied, current knowledge
about the condition, possible expectations and meanings
associated with research results [23], time, or conve-
nience factors involved in participating [20].
The perspective of other stakeholders, like institutional
review board chairs, has been addressed as well by Bes-
kow et al. [24]. The authors found that “there is unlikely to
be a “one-size-fits-all” solution, but rather several ethically
acceptable approaches to genotype-driven recruitment
depending on context” [24]. This paper highlighted the
importance of addressing the re-contact for further
research in the original informed consent (also suggested
by Beskow et al. [21]), of using a lay language and
clear communication with participants about current
knowledge in the research field that they are involved in
(also suggested by Minion et al., and Michie et al., and
Beskow et al. [15, 19, 21] respectively), and of the clinical
validity of research results to be communicated [24]. As a
whole, these studies showed the unresolved tensions in
RbG studies and provided both solutions and recommen-
dations (see Table 1, and recommendations suggested by
Beskow et al. [2]). The design of a generalized RbG policy
is difficult due to the complexity of the context, as
described above.
RbG studies are often conducted as sub-studies within
the framework of a larger-scale research study, which can
be longitudinal, long term, biobank based, and with broad
aims. The most recently published RbG studies included in
our literature review were conducted in Europe, mostly in
the frame of population studies such as the Cambridge
BioResource [25, 26], the Avon Longitudinal Study of
Parents and Children [27, 28], the Exeter 10000 study [29],
the Estonian Biobank of the Estonian Genome Center [30],
the PPP-Botnia study [31], and other types of study
[32, 33]. These RbG studies were designed to understand a
variety of diseases, conditions, and topics, such as inflam-
matory bowel disease [25], arterial and venous diseases
[26], schizophrenia [27], cardiovascular disease [28], level
of adiponectin [29], familial hypercholesterolaemia [30],
type 2 diabetes [31], anxiety disorders [32], and predis-
position to hypertriacylglycerolaemia [33]. Where the var-
iant(s) under study had clinical implications and treatment
options for the participant and their relatives, genetic
counselling, the disclosure of the carrier status, and further
tests for family members were offered [30]. We observed
that, in general, details on the type of informed consent and
re-contacting strategy were usually only briefly described.
On the other hand, when discussing the choice of RbG
design, authors of biomedical RbG papers largely justified
their approach with scientific arguments (e.g. statistical
efficiency and power, ease of data collection, and max-
imizing resources [32–37]), thus demonstrating more of a
focus on the researchers perspective. Based on this obser-
vation (the perceived lack of discussion of the ethical issues
at stake when conducting RbG studies), we decided to
embed an empirical study into the pilot RbG study, in order
to directly collect feedback on the research study from the
participants, with a view to improving our study design and
be better placed to address participants’ views in the future.
In both RbG studies and the return of research results to
study participants, the disclosure of potentially unwanted or
distressing information during re-contact might occur,
necessitating a reflection on how best to handle the com-
munication with participants In view of this commonality,
we drew upon the findings obtained from a previously
conducted qualitative study with CHRIS participants on the
return of results (own unpublished observation). In order to
tackle the issue of disclosure in a nuanced way and to meet
the expectations of participants, data from the return of
results interviews were used as a basis to develop the
questionnaire for the empirical study embedded in the pilot
RbG study.
To enrich the key ethical issues identified in the literature
with the clinical experience of experts, we engaged in a
discussion on RbG with nine clinical geneticists, working at
the hospitals in Bolzano, Verona, and Bologna. We sought
their view because it is of relevance for the medical and
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Table 1 Participant perspective on RbG issues according to the reviewed literature.
Findings Recommendations for researchers
Understanding the rationale of
RbG-designed studies
–Participants had basic knowledge of genetics and
limited interest in specific study designs (e.g. RbG)
[15].
–Former participants in an RbG study did not realize
that their recruitment was based on being carriers of
genetic variants of interest for researchers found
through a previous study, and did not recall that they
received their individual research results [19, 22].
–Researchers should highlight the complexity of
scientific research by offering participants suitable
information and opportunities for reflection [15].
–In order to avoid misunderstandings, researchers
should explain to participants notions of research
study design [19].
–During recruitment in paediatric research, researchers
should address potential benefits and risks for all the
possible stakeholders [20].
–Researchers should clearly communicate to
participants the current state of knowledge in their
field of research [21].
Experience of participation in
genetic research
–A general positive view on research participation
overall by study participants was based on trust,
solidarity, and reciprocity, which developed through
the long-term relationship with the study and
participant’s expertise as data provider [15].
–Patient-participants and general population biobank
participants understood their roles as research
participants differently [19].
–Possible benefits for their child and for other
stakeholders, altruism and positive action were the
main motivations for the participation in genetic
research of parents of children with a disease [20].
–Parental perception of the participation-associated
risks and benefits for their child differed according to
the type of disease with which their children were
affected [20].
–Researchers should consider the burden (e.g. time
needed, inconvenience) on the parents/family of
minors with a disease, when the minor participates in
research [20].
Expectations associated with
and the experience of
recruitment in RbG studies
–Patient-participants and general population biobank
participants perceived their recruitment in RbG
studies differently [19].
–Based on altruism and a positive attitude towards
research, participants found re-contact for research
recruitment and for RbG-designed studies acceptable
[21].
–Participant preference for being re-contacted for future
research varied according to study population and
study design [21].
–Trust played a role in the acceptability of re-contact
[21].
–The possibility of re-contact for further research
recruitment should be disclosed in the original
informed consent [20].
–When designing RbG studies, researchers should
know their study population well in order to develop
tailored research practices [21].
–Researchers should plan recruitment according to
context (general population or disease-specific cohort;
conditions in the original consent; access to samples
and data) [22].
–Contextual factors and empirical evidence should
inform the design of genotype-driven recruitment
[21].
–When designing RbG studies, researchers should




–Participants’ status (e.g. belonging to a disease-
specific cohort or to a general population biobank)
influenced the perceived meaningfulness of genetic
research results (validity and utility), views about the
return of individual genetic research results, and
desire of receiving individual research results [22].
–Patient-participants expressed layered expectations
about return of results: individual genetic research
results were assumed to give answers to questions
about specific issues (reasons for the researchers
interest in a specific participant, knowledge of the
disease under study or the participant themselves,
heritability of the disease, possible actions) [23].
–Patient-participants’ perception of risks and benefits
–The recommended guidelines for returning only
results of clinical utility may not be the most suitable
approach in RbG studies [21].
–The nature of the results (validity and utility) and the
context (participant population and participant’s
relationship with researchers) should be considered in
the decision of whether or not to disclose the
individual genetic research results [22].
–If individual or aggregate genetic research results are
disclosed during recruitment, researchers should
thoroughly explain to patient-participants the nature
of their research findings and any limitations [23].
–In the case of disclosure of individual genetic research
results during the recruitment process, researchers
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ethical implications of reporting genetic information to
study participants. Specifically, D.M. and M.K. discussed
possible strategies for communicating genetic findings with
members of the Clinical Genetics Unit in Bolzano, which
will play a vital role in future RbG studies in CHRIS
because it is assigned the task of providing necessary
genetic counselling within an RbG framework, under spe-
cific conditions. Together with the Bolzano Clinical
Genetics Unit, we identified four scenarios of inherited
genetic disease (for breast cancer, Parkinson’s disease (PD),
Huntington’s disease, and malignant hyperthermia), to serve
as a simplified representation of the complexities of inter-
pretation for a genotyping result in terms of associated
pathology. The four diseases differed by mode of inheri-
tance, genotype-associated disease risk, age at onset, pre-
vention, treatment, and clinical severity, thereby providing
an acceptable typology model of genotyping results. This
model has been used in a return of research results study to
facilitate the discussion on the views on the return of
individual genetic results, by showing a panel of results
which will have a very different impact on health: for
example, participants were asked whether they would like
to receive their genetic results about diseases such as
Huntington’s disease, where being carrier of the responsible
gene variant results in 100% risk of developing the disease,
50% risk of transmitting the disease to their children, and
for which there is no cure and no prevention. Each disease
served to represent a different scenario (own unpublished
observations). The model was occasionally used during the
interviews conducted in the empirical study reported here, if
the conversation raised the opportunity. In this case, it
served as a summary of the variables that participants might
find relevant in their decision in participating in research
about genetic diseases, and to stimulate reflection on the
impact that the information received during recruitment and
participation may have (e.g. emotional impact). The
description of the diseases in this model has been integrated
into the information provided for the CHRIS study
informed consent, revised for the first follow-up phase
(commenced October 2019) [38].
Through the steps described above, we identified several
key points to be addressed both in the design of our pilot
RbG study and also in a potential general RbG policy:
(1) The option for re-contact for further research inserted
into the informed consent (to legally be able to re-
contact participants according to their autonomous
choice).
(2) To address the return of individual research results in
the informed consent where individuals make an
autonomous specific choice addressing the willing-
ness to receive information on their genetic data,
Table 1 (continued)
Findings Recommendations for researchers
of disclosure of individual genetic research results
may be different compared to that of population study
participants [21].
–Parents of children with a disease were interested in
receiving individual genetic research results about
their children for clinical utility, reproductive
planning, explanation of the etiology of the disease,
proactive behaviour change [20].
–The return of individual genetic research results might
have a psychological impact on parents of children
with a disease [20].
–Parents of children with a disease would like to be
able to decide about receiving or not their child’s
individual genetic research results [20].
–Parental perception of the risks and benefits of
receiving individual genetic research results of their
children differed according to the type of disease with
which their children were affected [20].
–Participants’ views on disclosure of individual genetic
research results varied according to study type [21].
–Participants showed interest in receiving information
on aggregate research results to be updated about the
study and for reciprocity reasons [21].
–Participants showed moderate interest in receiving
communication of research outcomes [15].
–Participants’ low expectations of receiving individual
research results relied on the acceptance of the non-
disclosure policy of the study [15].
should provide clear and appropriate written and oral
explanations, by taking into account possible
meanings associated with those results [22].
–In case individual genetic research results are offered
to parents of children with a disease, researchers
should clearly explain the meaning and validity of
such results [20].
–Researchers should investigate (e.g. through
participants’ focus groups or by addressing physicians
or patient advocacy organizations) and identify the
expectations of patient-participants associated with
individual or aggregate genetic research results [23].
–Any decision about the communication of individual
research results should be taken by considering
participants’ needs and perspectives, which can be
acknowledged through participant engagement in
governance or involvement in empirical studies [15].
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explicitly addressing the right to know and not
to know.
(3) The availability of information about the genetic basis
of re-contact for RbG studies that addresses the right
to be informed and provides the basis for an informed
choice.
(4) A clear communication on the rationale for returning
(or not) research results for transparency, and again to
ensure that individuals are aware of the process.
Design of the pilot RbG study
Feasibility assessment
For an RbG study to be acceptable in the first place, any re-
contact must be covered by the consent given at the time of
recruitment. In the original CHRIS informed consent form,
which is a dynamic-based consent [17], participants could
choose among different options for re-contact. There are
two points in this consent that addressed the re-contact, each
with a different purpose. In one option, participants could
decide whether they wanted (or not) to be re-contacted for
communication and/or further studies. In the other option,
they could decide if they wished to be informed about
research results, including genetic results. In the latter case,
they could indicate their preferences through a series of
options: they could choose either to be informed (right to
know) or not to be informed (right not to know) or to be
informed only if actionability is possible (screening, ther-
apy, implications for family planning) or to be informed
only if results potentially affect their family’s health.
We concluded that legally and ethically the concomitant
choice of the options “agree to re-contact for communica-
tion and further studies” and “agree to re-contact for inci-
dental genetic findings” is in fact tantamount to approving
re-contact by genotype and, hence, meets eligibility
requirements for invitation to an RbG study.
Through a discussion with the ethics committee of the
Azienda Sanitaria dell’ Alto Adige and with local GPs, we
agreed on the feasibility and upon additional measures to
safeguard participants in the pilot study. First, the pilot
study should be focused on genetic variants with moderate
to low disease penetrance. Second, participants should be
provided further clarifications, if they so wished, in a timely
and easily accessible way.
Test case: heterozygosity for Parkin gene variants
Recent major sequencing efforts have revealed a surpris-
ingly large number of carriers of genetic variants reported to
cause disease under different modes of inheritance, who do
not exhibit overt symptoms of disease [39]. With indivi-
duals carrying many dozens of such function-altering var-
iants, an accurate estimate of genetic penetrance is
important to measure. For movement disorders, one of the
aims of the German DFG funded ProtectMove Research
Unit is to examine reduced penetrance for Parkin gene
(PRKN) variants usually disease-causing when inherited
recessively. Such biallelic disease-causing PRKN variants
(in a homozygous or compound heterozygous state) are
causative of PD through a recessive inheritance pattern,
with highly variable age of onset. Moreover, recessively
inherited heterozygous disease-causing variants in genes for
one disease may present as risk factors for PD. Such is the
case for biallelic variants in the glucocerebrosidase gene
(GBA) which cause Gaucher disease, whereas hetero-
zygosity at the same position strongly predisposes to PD.
This and other examples provide support for the notion that
disease-causing variants with reduced penetrance and
genetic risk factors are sometimes different expressions on a
continuum of effect sizes rather than representing a clearly
dichotomous situation. Notably, penetrance of GBA variants
was estimated as 7.6, 13.7, 21.4, and 29.7% at 50, 60, 70,
and 80 years, respectively [40]. Biallelic PRKN pathogenic
variants cause recessively inherited PD with high pene-
trance and typically earlier onset, whereas heterozygosity
only leads to a modestly increased risk for PD [41, 42].
Given that heterozygous PRKN variant carriers can develop
disease, the age of onset of carriers of heterozygous PRKN
variants has been shown to fall in between that of biallelic
variant carriers (earlier AAO) and sporadic PD patients
(later AAO), and imaging and neurophysiological studies
have revealed alterations in unaffected carriers of hetero-
zygous variants (for review, please see [41]), these obser-
vations provide the rationale to explore penetrance of
heterozygous pathogenic variants in PRKN, especially
considering their frequency in the population, which for
variants predicted to be pathogenic when inherited reces-
sively, is ~3% in CHRIS (own unpublished data), which is
much higher than the prevalence of PD [43].
Following the incorporation of additional measures
established with the ethics board and local GPs for parti-
cipant safety as detailed earlier, heterozygosity for PRKN
variants that can cause disease when inherited recessively,
or potentially dominantly with very low penetrance, was
chosen as a test case for the pilot RbG study.
Recruitment
Our pilot RbG study followed a matched recruitment design
with 25 pairs of PRKN variant carriers and matched non-
carriers. Each pair was chosen to be closely related, of the
same sex, and of similar age where possible. This approach
was taken for two main reasons, satisfying both the
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measures to safeguards participants and the clinical aim of
the pilot. Inviting carriers and non-carriers at the same time
without telling them their individual status potentially
reduces psychological strain. A matched recruitment design
reduces the risk of ascertainment bias due to possible pre- or
sub-clinical effects of PRKN gene variants.
Communication strategy
German was used for study communication, as it is the
preferred language among CHRIS participants [17]. Invitees
were sent an invitation letter and an information brochure
(for the original documents, see Supplementary Informa-
tion 1). In the information material, we explained the study
and its implications in lay language, aiming for clarity and
easy understanding of the contents by the reader. For
example, we avoided the use of gene symbols such as
“PRKN” and preferred “Parkin gene” instead. For the same
reason we avoided scientific jargon, e.g. we used “standard”
instead of “wild-type” when describing the gene. The bro-
chure was structured in the same way as the letter but
included more details relative to each section. In the letter,
we reminded the invitees of their participation in the CHRIS
study and of their expressed interest in participating in
further research (by previously agreeing to that in the
CHRIS informed consent). Both the letter and the brochure
illustrated the following points:
(1) The aim of the study, namely to carry out a deep
neurological examination to investigate protective
mechanisms against neurological diseases, with a
focus on PD.
(2) The concept of reduced penetrance and the need for
investigating the phenotype associated with a parti-
cular PRKN genotype.
(3) The study design, i.e. two groups of participants were
invited, with members of one group carrying the wild-
type PRKN gene and members of the other group
carrying variants of the gene.
(4) That only results relevant for the participant’s health
would be communicated. Their PRKN carrier status
would not be disclosed as no clinical benefits nor
direct individual consequences are currently known.
We concluded the letter by announcing an upcoming
phone call from the CHRIS study assistants to fix an
appointment and the contact details (phone number) of the
CHRIS study for further questions and clarifications.
Since the consequences of PRKN gene heterozygosity
are mostly unknown, we disclosed only the type of genetic
variant under study, but not the carrier status of the
addressee. We decided that the communication of the
individual carrier status, with the uncertainty regarding
clinical implications, would potentially cause distress to
participants. In the information material, we clarified that
current findings suggest that PRKN heterozygosity may
increase the risk of neurological symptoms. We highlighted
the possibility that the addressee could be carrier of either
status. To comply with the additional measures to safeguard
participants described above, a direct telephone number for
answering further questions and for formal enrolment was
made available from the date the invitation letters were sent
out. Consent was obtained at the study centre, where
explanatory material was also available alongside the
information provided verbally by study nurses and doctors.
If participants wished to ask questions or requested further
clarification during the medical examination, a specialist
medical doctor was available to respond. If specific out-
comes of the clinical examination required medical follow-
up, the participant was referred to suitable specialists.
Preliminary data and findings
Participation
Out of the 58 CHRIS participants invited by mail to parti-
cipate in our RbG study, 50 (86%) agreed. The main reasons
for non-participation were availability during the week of the
pilot study. An additional relative of one carrier, interested in
undergoing the clinical examination, asked also to be
included, to which we agreed, but did not include their data
in the subsequent analysis because of the self-referral.
Feedback from participants
As a preliminary finding within the empirical study, most
participants reported to be at ease with the recruitment process
and with the non-disclosure of their carrier status. They were
satisfied that they had the chance to have their concerns duly
addressed. Only one person experienced anxiety when
receiving the invitation to participate, but was reassured in a
phone conversation with a study assistant.
Lessons learned and recommendations for
RbG policy development
Context
The literature review revealed that when designing an RbG
study, it is key to consider the context of the study. The
dynamic consent model adopted by CHRIS facilitates the
ongoing communication between researchers and partici-
pants, and offers an easy way of informing CHRIS parti-
cipants about new study approaches, such as RbG. In our
Balancing scientific interests and the rights of participants in designing a recall by genotype study 1153
experience, CHRIS participants demonstrate a general
positive attitude towards research and participation and trust
towards the study (own unpublished results). The focus of
the pilot RbG study (research into the mechanisms of PD)
fits well into the main scope of the CHRIS study, i.e. the
study of cardiovascular, neurological, psychiatric, oncolo-
gic, and metabolic conditions. These aspects combined
might have played a role on the very high participation rate
in the pilot and on the generally positive attitude towards
participation. The participation rate of the RbG pilot study
was slightly higher than that of other sub-studies conducted
in the frame of the CHRIS study (own unpublished
observation).
Feasibility, re-contact, and communication
The framework of re-contact very much depends on whe-
ther re-contact was envisaged during the consent process of
the original study. Based on the experience from our pilot
study, we think that the possibility of future RbG studies
should be addressed in the consent of original cohort studies
as standard because RbG studies might entail disclosure of
sensitive data and individuals have the right to refuse this
information or to express the willingness to be informed.
Along with appropriate information, this would provide
cohort members an introduction to the concept, and an early
chance to decide whether or not they want to be involved in
such studies in general. At the time of the pilot study, the
informed consent of the CHRIS study addressed the return
of research results with several options, and did not speci-
fically refer to RbG. We concluded, however, that the
concomitant choice of accepting to be re-contacted for
communication and further research and agreeing to be re-
contacted with research results (relevant for health) by the
participant was acceptable as a condition for invitation to an
RbG study also in terms of legal requirements. When the
first follow-up phase of the CHRIS study started in 2019,
the information material of the informed consent was enri-
ched with specific examples for the typology of genetic
diseases that may form the basis of such further RbG stu-
dies, developed together with genetic counsellors, in order
to offer participants a more nuanced perspective on the
meaning and implications of carrying particular genetic
variants.
The ideal framework of the information process, in a
general consent setting, should aim to balance between the
practicability of the consent procedure and the amount of
provided information. We recommend that the commu-
nication strategy be adjusted to the significance of the
variant(s) in question, e.g. while the carrier status for a
variant of unknown significance may be communicated by
mail, professional genetic counselling is required for var-
iants with severe pathogenic implications. In Italy, the
communication of individual genetic results, especially in
the case of disease-causing implications, is usually done
through genetic counselling. In this context, the role of
informed consent is to pre-assess the willingness of people
to be involved in an informational procedure by genetic
counsellors, in case variants are found for RbG. This means
that, in some cases, individuals should be contacted for
proper disclosure/non-disclosure by genetic counsellors,
according to clinical severity and actionability. Considering
that the PRKN variants under study in our pilot RbG study
are usually highly penetrant in a recessive inheritance mode
and that we were studying heterozygous carriers with much
reduced, or negligible penetrance, we did not set up any
professional genetic counselling, which would be required
as part of a study for variants with dominant inheritance and
severe pathogenic implications. All participants in our pilot
reported to be at ease with the recruitment strategy used. We
also recommend including, as part of the setup of an RbG
study, a point of direct contact (preferably by telephone) for
potential participants, in order to collect and respond to
potential queries and worries immediately. One invitee in
our pilot study made use of this opportunity after receiving
the invitation, and their concerns were sufficiently
addressed.
As yet, no clear guidelines exist regarding the type of
genetic variants that may be reasonably disclosed to parti-
cipants in RbG studies. In our pilot study, we disclosed the
genetic variant under investigation to invitees, but not their
individual carrier status. This approach was met with ease
by the participants. It may be possible that with the specific
test case chosen for our pilot study (i.e. heterozygosity for
low-penetrance PRKN variants), variant-based re-contact
generates less anxiety than when being confronted with
information of variants with a demonstrated major impact
on health. The expected low clinical impact of these var-
iants is also a likely explanation of why most participants
deemed the non-disclosure of their carrier status acceptable.
However, this does not preclude that, with an RbG study
involving variants that cause disease recessively, re-contact
can create tensions and anxiety in potential study
participants.
Stakeholder engagement
Studies that did not foresee RbG in their original consent
should engage participants and other stakeholders in the
design of an appropriate RbG policy. In our experience,
stakeholder contribution was very valuable for the devel-
opment of practical solutions addressing the ethical issues
raised by RbG studies as well as for designing suitable
research tools for investigating the attitudes and expecta-
tions of participants. We recommend consulting stake-
holders in the design phase of such a study, as they can
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provide valuable insights for both the design of tailored
strategies and general issues. We consulted several key
partners in connecting the CHRIS scientists to the partici-
pants, including clinical geneticists, already involved in the
CHRIS study when genetic counselling is needed, the ethics
board, which is an essential part of the governance of the
CHRIS study, and GPs, which play an important role in
liaising with the community. CHRIS participants were
engaged at different levels. Findings from a previously
conducted empirical study on return of research results
provided the basis for the investigation of participants’
views on RbG. Conducting an empirical study embedded in
an RbG scientific study allowed us to obtain direct feedback
from participants on their participation in an RbG study.
If feasible (in terms of resources and time constrains,
number of recruited participants, and design of the study),
such an embedded empirical study design would be a
valuable strategy for shaping policy, because findings will
be useful for understanding the specific context of the study,
while designing and implementing an appropriate dynamic
adjustment of the RbG policy. In addition, an embedded
study design necessitates a close collaboration between
researchers with different professional expertise (such as
basic or clinical researchers and specialists in ethics), thus
having also a bidirectional educational impact. By increas-
ing awareness of the challenges posed by the re-contact of
participants and the disclosure of individual genetic infor-
mation, scientists be better able to reflect productively upon
their own study design. The sharing of experiences, solu-
tions, and tools from RbG studies should be widely
encouraged. It is in this spirit we report in our pilot study
and the steps we took in the process of a CHRIS RbG policy
and offer the tools and insights gained therein.
Conclusion
An RbG policy should balance the duty to provide infor-
mation on the scientific rationale for recruitment with the
right of the study participants to not to know sensitive
information, while also trying to minimize the risk of
deceiving participants by not informing them properly. Here,
we outline the steps that we undertook in the policy building
process for the CHRIS study. The difficulties in developing
an acceptable and practicable RbG policy are to be found in
those aspects of disclosing genetic information (informed
consent, communication, and recruitment). By reporting on
our experience in designing the workflow for the RbG pilot
study, we aim to contribute to the design of best practices and
tailored policy, and to participate in the reflection on research
methodology in the field of RbG studies.
Our approach in understanding how best to design and
conduct RbG studies in an ethically acceptable way and
potentially draft policy and guidelines for best practices in
RbG, included different steps and addressed the main
ethical issues from different perspectives, which included
reviewing the literature, consulting stakeholders, and col-
lecting feedback from participants through an empirical
study. The research on RbG best practices and policy we
conducted and described here aimed to respond to different
interests at stake: those of scientists, interested in conduct-
ing genetic studies to functionally understand the effects of
genetic variants in health and disease, and those of parti-
cipants, interested in having their rights respected and their
wishes and expectations addressed, while participating in
research. Based upon the insights gained through this
policy-development process, we are currently working on a
draft for a comprehensive RbG policy for future use and
additional testing in CHRIS-based RbG studies.
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